Antitope -- Antitope Ltd. today announced a research collaboration with Zyngenia, Inc. (“Zyngenia”) whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of a series of therapeutic ZybodyTM molecules being developed by Zyngenia to address multiple biological targets with single agents.
